N-(2-{4-[({[(2,2,7,7-2H4)azepan-1-yl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-5-methyl-1,2-oxazole-3-carboxamide

• ChemBase ID: 169646
• Molecular Formular: C20H27N5O5S
• Molecular Mass: 449.52388
• Monoisotopic Mass: 449.17328999
• SMILES: C(=O)(NCCc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1)c1cc(on1)C
• Canonical SMILES: Cc1onc(c1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1
• InChI: InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
• InChIKey: ZKUDBRCEOBOWLF-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-(2-{4-[({[(2,2,7,7-^2H₄)azepan-1-yl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-5-methyl-1,2-oxazole-3-carboxamide
• IUPAC Traditional name: N-{2-[4-({[(2,2,7,7-^2H₄)azepan-1-yl]carbamoyl}aminosulfonyl)phenyl]ethyl}-5-methyl-1,2-oxazole-3-carboxamide
• Synonyms: N-[2-[4-[[[[(Hexahydro-1H-azepin-1-yl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-3-isoxazolecarboxamide-d4; 4-[4-[β-(5-Methylisoxazole-3-carboxamido)ethyl]phenylsulfonyl]-1,1-hexamethylenesemicarbazide-d4; BS 4231-d4; Glisepin-d4; Glisoxepide-d4; Pro-Diaban-d4; Pro-Diaben-d4; RP 22410-d4; Glisoxepid-d4

Database IDs

• PubChem SID: 162263778
• PubChem CID: 71317079

CALCULATED PROPERTIES

• Acid pKa: 4.066667
• H Acceptors: 6
• H Donor: 3
• LogD (pH = 5.5): 0.59831023
• LogD (pH = 7.4): 0.49457988
• Log P: 1.4359764
• Molar Refractivity: 115.8573 cm^3
• Polarizability: 44.381973 Å^3
• Polar Surface Area: 133.64 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: true

DETAILS

Toronto Research Chemicals - G410602

Labelled Glisoxepid (G410600). Glisoxepid is used as an antidiabetic drug. Glisoxepid is a sulfonylurea derivative used in the treatment of diabetes mellitus type 2.

REFERENCES

• Schulz, M., et al.: Pharmazie, 58, 447 (2003)
• Viswanathan, C., et al.: Pharm. Res., 24, 1962 (2003)
• Drees, J., et al.: Clin. Chem., 55, 126 (2003)